Clinical Trial: The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)

U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07065968) titled 'The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)' on July 04.

Brief Summary: A multicenter, open-label, randomized study to report the efficacy and safety of teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with newly diagnosed primary immune thrombocytopenia (ITP).

Study Start Date: July 15

Study Type: INTERVENTIONAL

Condition: Immune Thrombocytopenia (ITP)

Intervention: DRUG: Teriflunomide

Teriflunomide 14 mg orally once daily for 24 weeks.

DRUG: Dexameth...